Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA Following Liver Transplantation
Status:
Unknown status
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is an investigator initiated study at the University of California, Los Angeles (UCLA)
funded by Novartis looking at using a combination of immunosuppressive drugs in liver
transplant patients that are at risk of developing kidney problems. Kidney problems following
liver transplants is the most problematic issue facing liver transplant patients today.
This study will generate information in this area of high unmet medical need utilizing
basiliximab and Myfortic and using a reduced dose of tacrolimus, one of the current standard
of care medications, after kidney function has normalized.
This study will enroll 60 subjects. 30 subjects in each of the two groups. Subjects will be
followed for 1 year after liver transplant.